会員登録
ログイン
【4880】セルソース
再生医療関連事業・コンシューマー事業・再生医療センター
類似企業：
【業界1位】
小野薬品工業
【業界1位】
小野薬品工業
売上高
営業利益
経常利益
当期利益
{{models[key].tabname}}
| 決算期 | 日付 | 予・実 | 売上高 (百万円) |
対前回 | 修正率 | 修正率 | 営業利益 (百万円) |
対前回 | 修正率 | 修正率 | 経常利益 (百万円) |
対前回 | 修正率 | 修正率 | 当期利益 (百万円) |
対前回 | 修正率 | 修正率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024.10 | 2024/09/12 | Q3予 | 4,374 | ↓ | -18.5% | -18.5% | 420 | ↓ | -58.1% | -58.1% | 527 | ↓ | -49.2% | -49.2% | 417 | ↓ | -42.0% | -42.0% |
| 2024.10 | 2024/06/13 | Q2予 | 5,368 | → | 0.0% | 0.0% | 1,003 | → | 0.0% | 0.0% | 1,037 | → | 0.0% | 0.0% | 719 | → | 0.0% | 0.0% |
| 2024.10 | 2024/03/11 | Q1予 | 5,368 | → | 0.0% | 0.0% | 1,003 | → | 0.0% | 0.0% | 1,037 | → | 0.0% | 0.0% | 719 | → | 0.0% | 0.0% |
| 2024.10 | 2023/12/15 | 当初予 | 5,368 | - | - | - | 1,003 | - | - | - | 1,037 | - | - | - | 719 | - | - | - |
| 2023.10 | 2023/12/15 | 実 | 4,510 | ↓ | -6.2% | -13.1% | 1,221 | ↓ | -13.5% | -24.9% | 1,194 | ↓ | -13.9% | -26.5% | 923 | ↓ | -5.9% | -9.9% |
| 2023.10 | 2023/09/19 | 修正予 | 4,806 | ↓ | -7.4% | -7.4% | 1,411 | ↓ | -13.2% | -13.2% | 1,386 | ↓ | -14.7% | -14.7% | 981 | ↓ | -4.2% | -4.2% |
| 2023.10 | 2023/09/13 | Q3予 | 5,192 | → | 0.0% | 0.0% | 1,625 | → | 0.0% | 0.0% | 1,625 | → | 0.0% | 0.0% | 1,024 | → | 0.0% | 0.0% |
| 2023.10 | 2023/06/14 | Q2予 | 5,192 | → | 0.0% | 0.0% | 1,625 | → | 0.0% | 0.0% | 1,625 | → | 0.0% | 0.0% | 1,024 | → | 0.0% | 0.0% |
| 2023.10 | 2023/03/14 | Q1予 | 5,192 | → | 0.0% | 0.0% | 1,625 | → | 0.0% | 0.0% | 1,625 | → | 0.0% | 0.0% | 1,024 | → | 0.0% | 0.0% |
| 2023.10 | 2022/12/14 | 当初予 | 5,192 | - | - | - | 1,625 | - | - | - | 1,625 | - | - | - | 1,024 | - | - | - |
| 2022.10 | 2022/12/14 | 実 | 4,273 | ↑ | +5.5% | +26.1% | 1,571 | ↑ | +17.6% | +40.5% | 1,583 | ↑ | +17.8% | +41.6% | 1,017 | ↑ | +22.1% | +50.2% |
| 2022.10 | 2022/09/13 | Q3予 | 4,050 | → | 0.0% | +19.5% | 1,336 | → | 0.0% | +19.5% | 1,344 | → | 0.0% | +20.2% | 833 | → | 0.0% | +23.0% |
| 2022.10 | 2022/08/31 | 修正予 | 4,050 | ↑ | +19.5% | +19.5% | 1,336 | ↑ | +19.5% | +19.5% | 1,344 | ↑ | +20.2% | +20.2% | 833 | ↑ | +23.0% | +23.0% |
| 2022.10 | 2022/06/13 | Q2予 | 3,389 | → | 0.0% | 0.0% | 1,118 | → | 0.0% | 0.0% | 1,118 | → | 0.0% | 0.0% | 677 | → | 0.0% | 0.0% |
| 2022.10 | 2022/03/16 | Q1予 | 3,389 | → | 0.0% | 0.0% | 1,118 | → | 0.0% | 0.0% | 1,118 | → | 0.0% | 0.0% | 677 | → | 0.0% | 0.0% |
| 2022.10 | 2021/12/13 | 当初予 | 3,389 | - | - | - | 1,118 | - | - | - | 1,118 | - | - | - | 677 | - | - | - |
| 2021.10 | 2021/12/13 | 実 | 2,922 | → | 0.0% | +15.1% | 992 | ↑ | +30.7% | +73.1% | 1,006 | → | 0.0% | +76.5% | 651 | → | 0.0% | +82.9% |
| 2021.10 | 2021/12/08 | 修正予 | 2,922 | ↑ | +4.0% | +15.1% | - | - | - | - | 1,006 | ↑ | +30.5% | +76.5% | 651 | ↑ | +37.3% | +82.9% |
| 2021.10 | 2021/09/10 | Q3予 | 2,810 | → | 0.0% | +10.7% | 759 | → | 0.0% | +32.5% | 771 | → | 0.0% | +35.3% | 474 | → | 0.0% | +33.1% |
| 2021.10 | 2021/06/14 | Q2予 | 2,810 | ↑ | +10.7% | +10.7% | 759 | ↑ | +32.5% | +32.5% | 771 | ↑ | +35.3% | +35.3% | 474 | ↑ | +33.1% | +33.1% |
| 2021.10 | 2021/03/15 | Q1予 | 2,539 | → | 0.0% | 0.0% | 573 | → | 0.0% | 0.0% | 570 | → | 0.0% | 0.0% | 356 | → | 0.0% | 0.0% |
| 2021.10 | 2020/12/14 | 当初予 | 2,539 | - | - | - | 573 | - | - | - | 570 | - | - | - | 356 | - | - | - |
| 2020.10 | 2020/12/14 | 実 | 1,855 | ↓ | -5.9% | -5.9% | 415 | ↑ | +13.7% | +13.7% | 412 | ↑ | +12.9% | +12.9% | 274 | ↑ | +17.1% | +17.1% |
| 2020.10 | 2020/09/10 | Q3予 | 1,972 | → | 0.0% | 0.0% | 365 | → | 0.0% | 0.0% | 365 | → | 0.0% | 0.0% | 234 | → | 0.0% | 0.0% |
| 2020.10 | 2020/06/15 | Q2予 | 1,972 | → | 0.0% | 0.0% | 365 | → | 0.0% | 0.0% | 365 | → | 0.0% | 0.0% | 234 | → | 0.0% | 0.0% |
| 2020.10 | 2020/03/16 | Q1予 | 1,972 | → | 0.0% | 0.0% | 365 | → | 0.0% | 0.0% | 365 | → | 0.0% | 0.0% | 234 | → | 0.0% | 0.0% |
| 2020.10 | 2019/12/12 | 当初予 | 1,972 | - | - | - | 365 | - | - | - | 365 | - | - | - | 234 | - | - | - |
| 2019.10 | 2019/12/12 | 実 | 1,611 | - | - | - | 326 | - | - | - | 303 | - | - | - | 199 | - | - | - |
